Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma

BACKGROUND: Vandetanib, added to cisplatin and radiation (RT) overcomes chemo RT and EGFR inhibitor resistance in head and neck squamous cell carcinoma (HNSCC) lines and models. METHODS: Patients with previously untreated HNSCC received vandetanib daily for 14 days (starting dose 100 mg) then vandet...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Head Neck
Huvudupphovsmän: Papadimitrakopoulou, VA, Frank, SJ, Cohen, EW, Hirsch, FR, Myers, JN, Heymach, JV, Lin, H, Tran, HT, Chen, CR, Jimeno, A, Nedzi, L, Vasselli, JR, Lowe, ES, Raben, D
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2015
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4414661/
https://ncbi.nlm.nih.gov/pubmed/25352401
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hed.23922
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk